Global Trust Asset Management LLC Boosts Stake in Boston Scientific Corporation $BSX

Global Trust Asset Management LLC raised its holdings in Boston Scientific Corporation (NYSE:BSX) by 578.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,956 shares of the medical equipment provider’s stock after purchasing an additional 2,520 shares during the quarter. Global Trust Asset Management LLC’s holdings in Boston Scientific were worth $318,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BSX. Vanguard Group Inc. raised its position in Boston Scientific by 1.3% in the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock valued at $13,577,311,000 after purchasing an additional 1,697,945 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Boston Scientific by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock valued at $1,070,387,000 after buying an additional 1,664,108 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Boston Scientific by 161.9% in the 1st quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider’s stock valued at $250,757,000 after buying an additional 1,536,663 shares during the period. Swedbank AB raised its holdings in shares of Boston Scientific by 114.5% in the 2nd quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock valued at $302,816,000 after buying an additional 1,505,019 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Boston Scientific by 10.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock valued at $1,426,779,000 after buying an additional 1,383,524 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $18,397,457 in the last 90 days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Up 0.1%

Shares of NYSE BSX opened at $98.20 on Monday. The stock has a market cap of $145.51 billion, a PE ratio of 58.45, a price-to-earnings-growth ratio of 2.36 and a beta of 0.65. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50. The business has a 50-day moving average price of $103.79 and a 200 day moving average price of $102.16.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business’s revenue was up 22.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on BSX. Robert W. Baird boosted their price objective on Boston Scientific from $117.00 to $123.00 and gave the company an “outperform” rating in a report on Thursday, July 24th. Needham & Company LLC reiterated a “buy” rating and issued a $121.00 price objective on shares of Boston Scientific in a report on Friday, September 19th. Raymond James Financial boosted their price objective on Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a report on Thursday, July 24th. Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Finally, UBS Group boosted their price objective on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $118.17.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.